CY1113630T1 - Αντισωματα αντι-χεπσιδινης και χρησεις εξ αυτωn - Google Patents
Αντισωματα αντι-χεπσιδινης και χρησεις εξ αυτωnInfo
- Publication number
- CY1113630T1 CY1113630T1 CY20121100986T CY121100986T CY1113630T1 CY 1113630 T1 CY1113630 T1 CY 1113630T1 CY 20121100986 T CY20121100986 T CY 20121100986T CY 121100986 T CY121100986 T CY 121100986T CY 1113630 T1 CY1113630 T1 CY 1113630T1
- Authority
- CY
- Cyprus
- Prior art keywords
- human
- hepcidin
- antibiotics
- antibodies
- count
- Prior art date
Links
- 229940066919 hepcidin Drugs 0.000 title abstract 2
- 239000003242 anti bacterial agent Substances 0.000 title 1
- 229940088710 antibiotic agent Drugs 0.000 title 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 abstract 2
- 102000009052 human hepcidin 25 Human genes 0.000 abstract 2
- 108700022871 human hepcidin 25 Proteins 0.000 abstract 2
- XJOTXKZIRSHZQV-RXHOOSIZSA-N (3S)-3-amino-4-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2S,3S)-1-[[(1R,6R,12R,17R,20S,23S,26R,31R,34R,39R,42S,45S,48S,51S,59S)-51-(4-aminobutyl)-31-[[(2S)-6-amino-1-[[(1S,2R)-1-carboxy-2-hydroxypropyl]amino]-1-oxohexan-2-yl]carbamoyl]-20-benzyl-23-[(2S)-butan-2-yl]-45-(3-carbamimidamidopropyl)-48-(hydroxymethyl)-42-(1H-imidazol-4-ylmethyl)-59-(2-methylsulfanylethyl)-7,10,19,22,25,33,40,43,46,49,52,54,57,60,63,64-hexadecaoxo-3,4,14,15,28,29,36,37-octathia-8,11,18,21,24,32,41,44,47,50,53,55,58,61,62,65-hexadecazatetracyclo[32.19.8.26,17.212,39]pentahexacontan-26-yl]amino]-3-methyl-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-4-oxobutanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)[C@@H](C)O)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@@H]4CSSC[C@H](NC(=O)[C@H](Cc5ccccc5)NC(=O)[C@@H](NC1=O)[C@@H](C)CC)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc1cnc[nH]1)NC3=O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N2)C(=O)NCC(=O)N4)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XJOTXKZIRSHZQV-RXHOOSIZSA-N 0.000 abstract 1
- 102000001554 Hemoglobins Human genes 0.000 abstract 1
- 108010054147 Hemoglobins Proteins 0.000 abstract 1
- 208000007502 anemia Diseases 0.000 abstract 1
- 238000004820 blood count Methods 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 210000003743 erythrocyte Anatomy 0.000 abstract 1
- 238000005534 hematocrit Methods 0.000 abstract 1
- 102000018511 hepcidin Human genes 0.000 abstract 1
- 108060003558 hepcidin Proteins 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 229910052742 iron Inorganic materials 0.000 abstract 1
- 230000003472 neutralizing effect Effects 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 230000000770 proinflammatory effect Effects 0.000 abstract 1
- 210000001995 reticulocyte Anatomy 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Παρέχονται μονοκλωνικά αντισώματα που δεσμεύουν επιλεκτικά την ανθρώπινη χεπσιδίνη-25 και που χαρακτηρίζονται ότι έχουν υψηλή συγγένεια για την ανθρώπινη χεπσιδίνη-25 και ισχυρές εξουδετερωτικές ιδιότητες της ανθρώπινης ώριμης χεπσιδίνης. Τα αντισώματα της εφεύρεσης είναι χρήσιμα θεραπευτικώς για την αύξηση των επιπέδων σιδήρου ορού, του αριθμού καταμέτρησης δικτυοκυττάρων, του αριθμού καταμέτρησης ερυθροκυττάρων του αίματος, της αιμοσφαιρίνης, και/ή του αιματοκρίτη σε έναν άνθρωπο και για την αγωγή και διάγνωση των προαγόμενων από ώριμη χεπσιδίνη διαταραχών όπως είναι η αναιμία, σε ένα ανθρώπινο υποκείμενο.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98491007P | 2007-11-02 | 2007-11-02 | |
| EP08844586A EP2209806B1 (en) | 2007-11-02 | 2008-10-29 | Anti-hepcidin antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1113630T1 true CY1113630T1 (el) | 2016-06-22 |
Family
ID=40383701
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20121100986T CY1113630T1 (el) | 2007-11-02 | 2012-10-19 | Αντισωματα αντι-χεπσιδινης και χρησεις εξ αυτωn |
Country Status (34)
| Country | Link |
|---|---|
| US (3) | US7820163B2 (el) |
| EP (2) | EP2527368B1 (el) |
| JP (1) | JP5469076B2 (el) |
| KR (2) | KR20120107145A (el) |
| CN (1) | CN103492414B (el) |
| AR (1) | AR069062A1 (el) |
| AU (1) | AU2008318850B2 (el) |
| BR (1) | BRPI0819211A2 (el) |
| CA (1) | CA2704527C (el) |
| CL (2) | CL2008003190A1 (el) |
| CO (1) | CO6231037A2 (el) |
| CR (1) | CR11414A (el) |
| CY (1) | CY1113630T1 (el) |
| DK (1) | DK2209806T3 (el) |
| DO (2) | DOP2010000123A (el) |
| EA (1) | EA023406B1 (el) |
| ES (1) | ES2392123T3 (el) |
| HR (1) | HRP20120870T1 (el) |
| IL (1) | IL205355A (el) |
| JO (1) | JO2828B1 (el) |
| MA (1) | MA31886B1 (el) |
| MX (1) | MX2010004841A (el) |
| MY (1) | MY155708A (el) |
| NZ (2) | NZ598391A (el) |
| PE (1) | PE20091261A1 (el) |
| PL (1) | PL2209806T3 (el) |
| PT (1) | PT2209806E (el) |
| RS (1) | RS52592B (el) |
| SI (1) | SI2209806T1 (el) |
| TN (1) | TN2010000201A1 (el) |
| TW (1) | TWI409276B (el) |
| UA (1) | UA98983C2 (el) |
| WO (1) | WO2009058797A1 (el) |
| ZA (1) | ZA201003025B (el) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2008047485A1 (ja) * | 2006-10-17 | 2010-02-18 | 直久 友杉 | 活性型ヘプシジンを指標とした、鉄代謝異常の診断方法 |
| US8629250B2 (en) | 2007-02-02 | 2014-01-14 | Amgen Inc. | Hepcidin, hepcidin antagonists and methods of use |
| WO2008146903A1 (ja) * | 2007-05-31 | 2008-12-04 | Naohisa Tomosugi | 活性型ヘプシジンを指標とした、急性虚血性疾患の診断方法 |
| PE20091261A1 (es) | 2007-11-02 | 2009-08-17 | Lilly Co Eli | Anticuerpos anti-hepcidina |
| CA2722600C (en) * | 2008-05-01 | 2014-01-21 | Amgen Inc. | Anti-hepcidin antibodies and methods of use |
| UA103032C2 (uk) * | 2008-08-06 | 2013-09-10 | Елі Ліллі Енд Компані | Селективні антитіла проти гепсидину-25 та їх застосування |
| DE102009034150A1 (de) * | 2009-07-20 | 2011-01-27 | Fresenius Medical Care Deutschland Gmbh | Adsorbens zur Adsorption von Hepcidin |
| AR077892A1 (es) | 2009-08-20 | 2011-09-28 | Vifor Int Ag | Quinolinas antagonistas de la hepcidina |
| AR077958A1 (es) | 2009-08-27 | 2011-10-05 | Vifor Int Ag | Quinoxalinonas antagonistas de la hepcidina |
| AR077999A1 (es) | 2009-09-02 | 2011-10-05 | Vifor Int Ag | Antagonistas de pirimidin y triazin-hepcidina |
| EP2475643A1 (de) | 2009-09-07 | 2012-07-18 | Vifor (International) Ag | Neue ethandiamin-hepcidin-antagonisten |
| WO2011029832A1 (de) | 2009-09-09 | 2011-03-17 | Vifor (International) Ag | Neue thiazol- und oxazol-hepcidin-antagonisten |
| WO2011071368A1 (en) | 2009-12-11 | 2011-06-16 | Umc St. Radboud | Method for measuring hepcidin |
| EP3299386A1 (en) * | 2010-08-16 | 2018-03-28 | Pieris Pharmaceuticals GmbH | Binding proteins for hepcidin |
| US20120214803A1 (en) | 2011-02-18 | 2012-08-23 | Vifor (International) Ag | Novel Sulfonaminoquinoline Hepcidin Antagonists |
| EP2791684B1 (en) | 2011-12-12 | 2017-08-23 | Pieris Pharmaceuticals GmbH | Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulation |
| WO2014152006A2 (en) * | 2013-03-15 | 2014-09-25 | Intrinsic Lifesciences, Llc | Anti-hepcidin antibodies and uses thereof |
| CA2961917A1 (en) | 2014-09-22 | 2016-03-31 | Intrinsic Lifesciences Llc | Humanized anti-hepcidin antibodies and uses thereof |
| CN104945497B (zh) * | 2014-11-21 | 2018-04-03 | 南京国龙生物科技有限公司 | 一种新型抗菌肽Hep‑W及其制备方法和应用 |
| EP3261670A4 (en) | 2015-02-24 | 2018-08-01 | Rpeptide, LLC | Anti-tau antibodies |
| WO2016146587A1 (en) | 2015-03-13 | 2016-09-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Hepcidin antagonists for use in the treatment of inflammation |
| TWI789343B (zh) | 2016-02-01 | 2023-01-11 | 丹麥商碩騰丹麥有限公司 | 微流體分析系統、執行分析的微流體匣及方法 |
| WO2018234538A1 (en) | 2017-06-23 | 2018-12-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Hepcidin antagonist or agonist for use in the treatment of dysregulation of mo and/or mn metabolism |
| ES2759622T3 (es) | 2017-10-02 | 2020-05-11 | Certest Biotec S L | Anticuerpos anti-Dps y dispositivos de prueba para la detección de bacterias del género Campylobacter |
| CN114761013A (zh) | 2019-09-27 | 2022-07-15 | 迪斯克医药公司 | 治疗骨髓纤维化和相关病症的方法 |
| KR20230012539A (ko) | 2020-05-13 | 2023-01-26 | 디스크 메디슨, 인크. | 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체 |
| WO2022098812A1 (en) | 2020-11-04 | 2022-05-12 | Keros Therapeutics, Inc. | Methods of treating iron overload |
| CN117903311B (zh) * | 2024-03-20 | 2024-10-25 | 湖南卓润生物科技有限公司 | sST2特异性结合蛋白及其制备方法和应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU3774300A (en) | 1999-06-02 | 2000-12-18 | Genentech Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US6262247B1 (en) | 1999-08-30 | 2001-07-17 | Incyte Genomics, Inc. | Polycyclic aromatic hydrocarbon induced molecules |
| DE60231804D1 (de) * | 2001-05-25 | 2009-05-14 | Inst Nat Sante Rech Med | Verwendung von hepcidin zur herstellung eines arzneimittels zur behandlung von eisenhomöostase störungen |
| CN1173737C (zh) | 2002-10-21 | 2004-11-03 | 钱忠明 | Hepcidin(海魄喜定)在制药中的应用 |
| WO2004058044A2 (en) | 2002-11-19 | 2004-07-15 | Drg International, Inc. | Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids and therapeutic uses therefor |
| US8017737B2 (en) * | 2002-11-19 | 2011-09-13 | Hasan Kulaksiz | Diagnostic methods for diseases by screening for hepcidin in human or animal tissues, blood or body fluids; monoclonal antibodies specific to human hepcidin and associated uses therefor |
| US7411048B2 (en) | 2002-11-19 | 2008-08-12 | Drg International, Inc. | Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids |
| WO2005033327A2 (en) | 2003-09-29 | 2005-04-14 | Biosite Incorporated | Methods and compositions for the diagnosis of sepsis |
| US7723063B2 (en) * | 2004-04-28 | 2010-05-25 | Intrinsic Lifesciences | Methods for measuring levels of bioactive human hepcidin |
| EP1853630A1 (en) | 2004-10-22 | 2007-11-14 | Applied Molecular Evolution Inc. | Methods of optimizing antibody variable region binding affinity |
| WO2006062685A2 (en) | 2004-11-11 | 2006-06-15 | Affymax, Inc. | Novel peptides that bind to the erythropoietin receptor |
| KR101310000B1 (ko) | 2005-03-11 | 2013-09-25 | 싸이퍼젠 바이오시스템즈, 인코포레이티드 | 난소암 및 자궁내막암에 대한 바이오마커 : 헵시딘 |
| US8629250B2 (en) | 2007-02-02 | 2014-01-14 | Amgen Inc. | Hepcidin, hepcidin antagonists and methods of use |
| WO2009044284A1 (en) | 2007-10-02 | 2009-04-09 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Antibodies specific for human hepcidin |
| PE20091261A1 (es) | 2007-11-02 | 2009-08-17 | Lilly Co Eli | Anticuerpos anti-hepcidina |
| CA2722600C (en) | 2008-05-01 | 2014-01-21 | Amgen Inc. | Anti-hepcidin antibodies and methods of use |
| UA103032C2 (uk) * | 2008-08-06 | 2013-09-10 | Елі Ліллі Енд Компані | Селективні антитіла проти гепсидину-25 та їх застосування |
-
2008
- 2008-10-27 PE PE2008001837A patent/PE20091261A1/es not_active Application Discontinuation
- 2008-10-27 TW TW097141237A patent/TWI409276B/zh not_active IP Right Cessation
- 2008-10-27 JO JO2008486A patent/JO2828B1/en active
- 2008-10-27 AR ARP080104691A patent/AR069062A1/es unknown
- 2008-10-27 CL CL2008003190A patent/CL2008003190A1/es unknown
- 2008-10-29 ES ES08844586T patent/ES2392123T3/es active Active
- 2008-10-29 PL PL08844586T patent/PL2209806T3/pl unknown
- 2008-10-29 MX MX2010004841A patent/MX2010004841A/es active IP Right Grant
- 2008-10-29 KR KR1020127023660A patent/KR20120107145A/ko not_active Withdrawn
- 2008-10-29 KR KR1020107009633A patent/KR101335059B1/ko not_active Expired - Fee Related
- 2008-10-29 CN CN200880114428.1A patent/CN103492414B/zh not_active Expired - Fee Related
- 2008-10-29 US US12/260,125 patent/US7820163B2/en not_active Expired - Fee Related
- 2008-10-29 MY MYPI2010001992A patent/MY155708A/en unknown
- 2008-10-29 SI SI200830773T patent/SI2209806T1/sl unknown
- 2008-10-29 AU AU2008318850A patent/AU2008318850B2/en not_active Ceased
- 2008-10-29 RS RS20120466A patent/RS52592B/sr unknown
- 2008-10-29 EA EA201070553A patent/EA023406B1/ru not_active IP Right Cessation
- 2008-10-29 EP EP12172307.6A patent/EP2527368B1/en active Active
- 2008-10-29 BR BRPI0819211-1A patent/BRPI0819211A2/pt not_active IP Right Cessation
- 2008-10-29 CA CA2704527A patent/CA2704527C/en not_active Expired - Fee Related
- 2008-10-29 PT PT08844586T patent/PT2209806E/pt unknown
- 2008-10-29 NZ NZ598391A patent/NZ598391A/xx not_active IP Right Cessation
- 2008-10-29 EP EP08844586A patent/EP2209806B1/en active Active
- 2008-10-29 JP JP2010532186A patent/JP5469076B2/ja not_active Expired - Fee Related
- 2008-10-29 NZ NZ584997A patent/NZ584997A/en not_active IP Right Cessation
- 2008-10-29 WO PCT/US2008/081493 patent/WO2009058797A1/en not_active Ceased
- 2008-10-29 HR HRP20120870AT patent/HRP20120870T1/hr unknown
- 2008-10-29 DK DK08844586.1T patent/DK2209806T3/da active
- 2008-10-29 UA UAA201005156A patent/UA98983C2/uk unknown
-
2010
- 2010-04-22 CO CO10047542A patent/CO6231037A2/es active IP Right Grant
- 2010-04-26 DO DO2010000123A patent/DOP2010000123A/es unknown
- 2010-04-26 IL IL205355A patent/IL205355A/en not_active IP Right Cessation
- 2010-04-30 ZA ZA2010/03025A patent/ZA201003025B/en unknown
- 2010-04-30 TN TN2010000201A patent/TN2010000201A1/fr unknown
- 2010-04-30 MA MA32811A patent/MA31886B1/fr unknown
- 2010-05-05 CR CR11414A patent/CR11414A/es not_active IP Right Cessation
- 2010-08-31 US US12/872,172 patent/US8329174B2/en active Active
-
2012
- 2012-06-22 CL CL2012001710A patent/CL2012001710A1/es unknown
- 2012-10-19 CY CY20121100986T patent/CY1113630T1/el unknown
- 2012-12-07 US US13/708,059 patent/US8765129B2/en active Active
-
2013
- 2013-09-11 DO DO2013000205A patent/DOP2013000205A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1113630T1 (el) | Αντισωματα αντι-χεπσιδινης και χρησεις εξ αυτωn | |
| CY1119454T1 (el) | Αντισωματα εναντι cd38 για τη θεραπεια του πολλαπλου μυελωματος | |
| NL301089I2 (nl) | imlifidase | |
| CY1116886T1 (el) | C-met αντισωματα | |
| ATE461220T1 (de) | Anti-egfr-antikörper | |
| CR8698A (es) | Anticuerpos monoclonales al factor de crecimiento de hepatocito | |
| CY1122412T1 (el) | Ομοιοπολικα διασωματα καi χρησεις αυτων | |
| UA109633C2 (uk) | Антитіло людини проти тканинного фактора | |
| MX2009009226A (es) | Anticuerpos recombinantes para el tratamiento de infecciones con el virus respiratorio sincitial. | |
| CY1114271T1 (el) | Αντισωματα εξουδετερωσης, ανθρωπινου κυτταρομεγαλοϊου και χρηση αυτων | |
| EA200970694A1 (ru) | ПЭГИЛИРОВАННЫЕ Fab-ФРАГМЕНТЫ АНТИТЕЛ К ПЕПТИДУ Aβ | |
| CY1118549T1 (el) | Χρηση anti-vegf αντισωματος σε συνδυασμο με χημειοθεραπεια για τη θεραπευτικη αγωγη του καρκινου του μαστου | |
| UA116194C2 (uk) | Антитіло, яке специфічно зв'язується з людським альфа-синуклеїном | |
| EA201200277A1 (ru) | Антитела против респираторного синцитиального вируса (pcb) и способы их применения | |
| MEP53308A (en) | Novel peptides that bind to the erythropoietin receptor | |
| EA200701448A1 (ru) | Специфически связывающаяся с крипто-антигеном человека молекула (варианты), композиция на ее основе (варианты), способ получения молекулы, способ лечения посредством молекулы (варианты) и способ ингибирования крипто-экспрессии в клетке больного | |
| EP2535353A8 (en) | Monoclonal antibodies that bind to hGM-CSF and medical compositions comprising same | |
| EA201490677A1 (ru) | Связывающие антиген cd27l белки | |
| ATE517920T1 (de) | Humanisierte antikörper gegen interferon-alpha- rezeptor-1 (ifnar-1) | |
| CL2022003715A1 (es) | Tubulisinas y conjugados de proteinas-tubulisina | |
| CY1114811T1 (el) | Νεα κλασματα πρωτεϊνων γαλακτος και η χρηση τους για την προληψη ή τη θεραπεια των χρονιων φλεγμονωδων νοσων | |
| MX2014002762A (es) | Uso de proteina c-met para predecir la eficacia de anticuerpos de factor de crecimiento de anti-hepatocitos (hgf) en pacientes con cancer esofagico y gastrico. | |
| CY1117355T1 (el) | Μονοκλωνικα αντισωματα αντi-φερροπορτiνης 1 και χρησεις αυτων | |
| ATE497392T1 (de) | Therapie mit anti-cd4-antikörpern und bestrahlung | |
| ATE536887T1 (de) | Kovalente konjugate zwischen mit artemisinin verwandten endoperoxiden und eisentragenden proteinen und anwendungsverfahren |